Hoshino Y, Nishikawa K, Ito Y, Kuzushima K, Kimura H. Kinetics of Epstein-Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis. J Clin Virol. 2011;50(3):244–6.

Article  CAS  PubMed  Google Scholar 

Hue SSS, Oon ML, Wang S, Tan SY, Ng SB. Epstein–Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. Pathology. 2020;52(1):111–27.

Article  CAS  PubMed  Google Scholar 

Chen S, Wei A, Ma H, et al. Clinical features and prognostic factors of children with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center. J Pediatr. 2021;238:268–274.

Article  PubMed  Google Scholar 

Sprangers B, Riella LV, Dierickx D. Posttransplant lymphoproliferative disorder following kidney transplantation: a review. Am J Kidney Dis. 2021;78(2):272–81.

Article  PubMed  Google Scholar 

Hanafusa H, Yamaguchi H, Morisada N, et al. End-stage ADPKD with a low-frequency PKD1 mosaic variant accelerated by chemoradiotherapy. Hum Genome Var. 2024;11:17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei N, Wang Y, Wang J, Wu L, Wang Z. Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab. Bone Marrow Transpl. 2021;56(6):1449–51.

Article  CAS  Google Scholar 

Kania SP, Silva JMF, Charles OJ, et al. Epstein-Barr virus reactivation after paediatric haematopoietic stem cell transplantation: risk factors and sensitivity analysis of mathematical model. Front Immunol. 2022;13:903063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Law N, Logan C, Taplitz R. EBV reactivation and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients and its impact on HSCT outcomes. Viruses. 2024;16(8):1294.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lindsay J, Othman J, Yong MK, et al. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant. Transpl Infect Dis. 2021;23(5):e13719.

Article  CAS  PubMed  Google Scholar 

Orlando EH, Gould P, Cuzzo B, et al. Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV dnaemia. Blood Neoplasia. 2025;2(4):100160.

Article  PubMed  PubMed Central  Google Scholar 

Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transpl. 2005;5(12):2954–60.

Article  CAS  Google Scholar 

Pascual J. Post-transplant lymphoproliferative disorder—the potential of proliferation signal inhibitors. Nephrol Dial Transpl. 2007;22(Suppl 1):i27–35.

Article  CAS  Google Scholar 

Rotz SJ, Bhatt NS, Hamilton BK, et al. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update. Transplant Cell Ther. 2024;30(4):349–85.

Article  PubMed  PubMed Central  Google Scholar 

Kikkawa K, Tamaki M, Maruno K, et al. Kidney transplantation after ABO-incompatible hematopoietic stem cell transplantation: a case report and literature review. Transpl Immunol. 2024;87:102143.

Article  PubMed  Google Scholar 

Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet. 2000;356(9225):223–4.

Article  CAS  PubMed  Google Scholar 

Sawada A, Inoue M. Narrative review of chronic active EBV infection—advances in clinical management. Ann Lymphoma. 2021;5:1–14.

Article  Google Scholar 

Ando M, Ohashi K, Akiyama H, et al. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol Dial Transplant. 2010;25(1):278–82.

Article  PubMed  Google Scholar